Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.
Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback